Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inter-Laboratory Comparison of Chronic Myeloid Leukemia Minimal Residual Disease Monitoring

10 Aug 2007

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Chronic Myeloid Leukemia Treatments
Share to Lymphoma Diagnosis and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 17690211
DOI: 10.2353/jmoldx.2007.060134

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inter-Laboratory Comparison of Chronic Myeloid Leukemia Minimal Residual Disease MonitoringPMID 17690211Read ↗

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.Semantic proximity Read ↗

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.Semantic proximity Read ↗

Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center settingSemantic proximity Read ↗

Acute Lymphoblastic Leukemia: Monitoring Minimal Residual Disease as a Therapeutic PrincipleSemantic proximity Read ↗

Comparison of flow cytometry and next-generation sequencing in minimal residual disease monitoring of acute myeloid leukemia: One institute's practical clinical experience.Semantic proximity Read ↗

Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?Semantic proximity Read ↗

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspectsSemantic proximity Read ↗

Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.Semantic proximity Read ↗

Monitoring minimal residual disease in AML.Semantic proximity Read ↗

Present and future of molecular monitoring in chronic myeloid leukaemia.Semantic proximity Read ↗

Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.Semantic proximity Read ↗

Measurable residual disease in chronic myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.